Actinium Related Publications

(212)Pb-radioimmunotherapy induces G(2) cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease.

Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW. Mol Cancer Ther. 2012 Mar;11(3):639-48.

PMID: 22238365

Durable donor engraftment after radioimmunotherapy using α-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation.

Chen Y, Kornblit B, Hamlin DK, Sale GE, Santos EB, Wilbur DS, Storer BE, Storb R, Sandmaier BM. Blood. 2012 Feb 2;119(5):1130-8.

PMID: 22134165

Optimizing radioimmunoconjugate delivery in the treatment of solid tumor.

Huang CY, Pourgholami MH, Allen BJ. Cancer Treat Rev. 2012 Jan 4.

PMID: 22226242

Pre-Clinical Assessment of Lu-Labeled Trastuzumab Targeting HER2 for Treatment and Management of Cancer Patients with Disseminated Intraperitoneal Disease.

Ray GL, Baidoo KE, Keller LM, Albert PS, Brechbiel MW, Milenic DE. Pharmaceuticals (Basel). 2011 Dec 22;5(1):1-15.

PMID: 22229017

Yttrium-90 (90Y) in the principal radionuclide therapies: an efficacy correlation between peptide receptor radionuclide therapy,radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999-2009).

Goffredo V, Paradiso A, Ranieri G, Gadaleta CD. Crit Rev Oncol Hematol. 2011 Dec;80(3):393-410.

PMID:21388824

Clinical radioimmunotherapy--the role of radiobiology.

Pouget JP, Navarro-Teulon I, Bardiès M, Chouin N, Cartron G, Pèlegrin A, Azria D. Nat Rev Clin Oncol. 2011 Nov 8;8(12):720-34.

PMID: 22064461

Toxicity and relative biological effectiveness of alpha emitting radioimmunoconjugates.

Dahle J, Abbas N, Bruland ØS, Larsen RH. Curr Radiopharm. 2011 Oct;4(4):321-8.

PMID: 22202154

Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab.

Abbas N, Heyerdahl H, Bruland OS, Borrebæk J, Nesland J, Dahle J. EJNMMI Res. 2011 Aug 24;1(1):18.

PMID: 22214432

Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model.

Pagel JM, Kenoyer AL, Bäck T, Hamlin DK, Wilbur DS, Fisher DR, Park SI, Frayo S, Axtman A, Orgun N, Orozco J, Shenoi J, Lin Y, Gopal AK, Green DJ, Appelbaum FR, Press OW. Blood. 2011 Jul 21;118(3):703-11.

PMID: 21613259

Pretargeted radioimmunotherapy with α-particle emitting radionuclides.

Lindegren S, Frost SH. Curr Radiopharm. 2011 Jul;4(3):248-60.

PMID:22201711

Tositumomab and iodine I 131 tositumomab (Bexaar).

Srinivasan A, Mukherji SK. AJNR Am J Neuroradiol. 2011 Apr;32(4):637-8.

PMID: 21436340

Cancer radioimmunotherapy.

Sharkey RM, Goldenberg DM. Immunotherapy. 2011 Mar;3(3):349-70.

PMID: 21395378

Clinical Management of Relapsed/Refractory Acute Myeloid Leukaemia.

Parikh, SA, Faderl S. European Haematology, 2010, 4: 43-6.

Current concepts and future directions in radioimmunotherapy.

Lin FI, Iagaru A. Curr Drug Discov Technol. 2010 Dec;7(4):253-62.

PMID:21034409

Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia.

Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, Divgi CR, Panageas KS,Heaney ML, Chanel S, Morgenstern A, Sgouros G, Larson SM, Scheinberg DA, Jurcic JG. Clin Cancer Res. 2010 Nov 1;16(21):5303-11.

PMID: 20858843

Radiolabeled antibodies for cancer treatment.

[Article in French]

Barbet J, Chatal JF, Kraeber-Bodéré F. Med Sci (Paris). 2009 Dec;25(12):1039-45.

PMID: 20035676

Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome.

Pagel JM, Gooley TA, Rajendran J, Fisher DR, Wilson WA, Sandmaier BM, Matthews DC, Deeg HJ, Gopal AK, Martin PJ, Storb RF, Press OW, Appelbaum FR.

Blood. 2009 Dec 24;114(27):5444-53.

PMID: 19786617

Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia.

Armistead PM, de Lima M, Pierce S, Qiao W, Wang X, Thall PF, Giralt S, Ravandi F, Kantarjian H, Champlin R, Estey E.

Biol Blood Marrow Transplant. 2009 Nov;15(11):1431-8.

PMID: 19822303

131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma.

Gopal AK, Pagel JM, Fromm JR, Wilbur S, Press OW.

Blood. 2009 Jun 4;113(23):5905-10.

PMID: 19332764

Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y.

Song H, Hobbs RF, Vajravelu R, Huso DL, Esaias C, Apostolidis C,Morgenstern A, Sgouros G. Cancer Res. 2009 Dec 1;69(23):8941-8.

PMID: 19920193

What can be expected from nuclear medicine tomorrow?

Barbet J, Kraeber-Bodéré F, Chatal JF. Cancer Biother Radiopharm. 2008 Aug;23(4):483-504.

PMID: 18771353

Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cells.

Friesen C, Glatting G, Koop B, Schwarz K, Morgenstern A, Apostolidis C,Debatin KM, Reske SN. Cancer Res. 2007 Mar 1;67(5):1950-8.

PMID: 17332322

Selective alpha-particle mediated depletion of tumor vasculature with vascular normalization.

Singh Jaggi J, Henke E, Seshan SV, Kappel BJ, Chattopadhyay D, May C, McDevitt MR, Nolan D, Mittal V, Benezra R, Scheinberg DA.

PLoS ONE. 2007 Mar 7;2:e267

PMID: 17342201

Non-invasive visualisation of the development of peritoneal carcinomatosis and tumour regression after (213)Bi-radioimmunotherapy using bioluminescence imaging.

Buchhorn HM, Seidl C, Beck R, Saur D, Apostolidis C, Morgenstern A, Schwaiger M, Senekowitsch-Schmidtke R.

Eur J Nucl Med Mol Imaging. 2007 Jan 6

PMID: 17206415

Influence of the linker on the biodistribution and catabolism of actinium-225 self-immolative tumor-targeted isotope generators.

Antczak C, Jaggi JS, LeFave CV, Curcio MJ, McDevitt MR, Scheinberg DA.

Bioconjug Chem. 2006 Nov-Dec;17(6):1551-60.

PMID: 17105236

Mitigation of radiation nephropathy after internal alpha-particle irradiation of kidneys.

Jaggi JS, Seshan SV, McDevitt MR, Sgouros G, Hyjek E, Scheinberg DA.

Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1503-12. Epub 2006 Feb 28.

PMID: 16503385

Renal tubulointerstitial changes after internal irradiation with alpha-particle-emitting actinium daughters.

Jaggi JS, Seshan SV, McDevitt MR, LaPerle K, Sgouros G, Scheinberg DA.

J Am Soc Nephrol. 2005 Sep;16(9):2677-89. Epub 2005 Jun 29.

PMID: 15987754

The promise of targeted {alpha}-particle therapy.

Mulford DA, Scheinberg DA, Jurcic JG. J Nucl Med. 2005 Jan;46 Suppl 1:199S-204S.

PMID: 15653670

Fractionated locoregional low-dose radioimmunotherapy improves survival in a mouse model of diffuse-type gastric cancer using a 213Bi-conjugated monoclonal antibody.

Bloechl S, Beck R, Seidl C, Morgenstern A, Schwaiger M, Senekowitsch-Schmidtke R.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7070s-7074s.

PMID: 16203804

Efforts to control the errant products of a targeted in vivo generator.

Jaggi JS, Kappel BJ, McDevitt MR, Sgouros G, Flombaum CD, Cabassa C, Scheinberg DA.

Cancer Res. 2005 Jun 1;65(11):4888-95.

PMID: 15930310

Cell death triggered by alpha-emitting 213Bi-immunoconjugates in HSC45-M2 gastric cancer cells is different from apoptotic cell death.

Seidl C, Schrock H, Seidenschwang S, Beck R, Schmid E, Abend M, Becker KF, Apostolidis C, Nikula TK, Kremmer E, Schwaiger M, Senekowitsch-Schmidtke R. Links

Eur J Nucl Med Mol Imaging. 2005 Mar;32(3):274-85. Epub 2004 Oct 2.

Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2.

Miederer M, McDevitt MR, Borchardt P, Bergman I, Kramer K, Cheung NK, Scheinberg DA.

Clin Cancer Res. 2004 Oct 15;10(20):6985-92.

PMID: 15501978

Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression.

Ballangrud AM, Yang WH, Palm S, Enmon R, Borchardt PE, Pellegrini VA, McDevitt MR, Scheinberg DA, Sgouros G.

Clin Cancer Res. 2004 Jul 1;10(13):4489-97.

PMID: 1524054

Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates.

Miederer M, McDevitt MR, Sgouros G, Kramer K, Cheung NK, Scheinberg DA.

J Nucl Med. 2004 Jan;45(1):129-37.

PMID: 14734685

Targeted actinium-225 in vivo generators for therapy of ovarian cancer.

Borchardt PE, Yuan RR, Miederer M, McDevitt MR, Scheinberg DA.

Cancer Res. 2003 Aug 15;63(16):5084-90.

PMID: 12941838

Myeloablative conditioning regimens for AML allografts: 30 years later.

Gupta V, Lazarus HM, Keating A.

Bone Marrow Transplant. 2003 Nov;32(10):969-78

PMID: 14595384

Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas.

Pagel JM, Hedin N, Subbiah K, Meyer D, Mallet R, Axworthy D, Theodore LJ, Wilbur DS, Matthews DC, Press OW.

Blood. 2003 Mar 15;101(6):2340-8. Epub 2002 Nov 21.

PMID: 12446461

Design and synthesis of 225Ac radioimmunopharmaceuticals.

McDevitt MR, Ma D, Simon J, Frank RK, Scheinberg DA.

Appl Radiat Isot. 2002 Dec;57(6):841-7.

PMID: 12406626

Targeted alpha particle immunotherapy for myeloid leukemia.

Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, Ballangrud AM, Hamacher KA, Ma D, Humm JL, Brechbiel MW, Molinet R, Scheinberg DA.

Blood. 2002 Aug 15;100(4):1233-9.

PMID: 12149203

Tumor therapy with targeted atomic nanogenerators..

McDevitt MR, Ma D, Lai LT, Simon J, Borchardt P, Frank RK, Wu K, Pellegrini V, Curcio MJ, Miederer M, Bander NH, Scheinberg DA. C, Molinet R.

Science. 2001 Nov 16;294(5546):1537-40.

PMID: 11711678

An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer.

McDevitt MR, Barendswaard E, Ma D, Lai L, Curcio MJ, Sgouros G, Ballangrud AM, Yang WH, Finn RD, Pellegrini V, Geerlings MW Jr, Lee M, Brechbiel MW, Bander NH, Cordon-Cardo C, Scheinberg DA. Cancer Res. 2000 Nov 1;60(21):6095-100. [MEDLINE record in process]

PMID: 11085533; UI: 20535983

In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen.

Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D, Bander NH. Cancer Res. 2000 Sep 15;60(18):5237-43.

PMID: 11016653; UI: 20468868

Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia.

Sgouros G, Ballangrud AM, Jurcic JG, McDevitt MR, Humm JL, Erdi YE, Mehta BM, Finn RD, Larson SM, Scheinberg DA.

J Nucl Med. 1999 Nov;40(11):1935-46.

PMID: 10565792; UI: 20029522

Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use.

McDevitt MR, Finn RD, Ma D, Larson SM, Scheinberg DA.

J Nucl Med. 1999 Oct;40(10):1722-7.

PMID: 10520715; UI: 99449025